MacroGenics, Inc. ( MGNX ) NASDAQ Global Select

Cena: 1.32 ( 1.15% )

Aktualizacja 06-23 21:17
NASDAQ Global Select
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 339
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 94%
Ilość akcji: 62 029 400
Debiut giełdowy: 2013-10-10
WWW: https://www.macrogenics.com
CEO: Dr. Scott Koenig M.D., Ph.D.
Adres: 9704 Medical Center Drive
Siedziba: 20850 Rockville
ISIN: US5560991094
Opis firmy:

MacRogelics, Inc., firma biofarmaceutyczna, rozwija i komercjalizuje terapeutyki oparte na przeciwciałach w celu leczenia raka w Stanach Zjednoczonych. Jego zatwierdzonym produktem jest Margenza (Margetuximab-CMKB), antagonista receptora naskórkowego 2 (HER2) receptora 2 (HER2), w połączeniu z chemioterapią, w leczeniu dorosłych pacjentów z przerzutowym rakiem piersi-dodatni, którzy otrzymali dwa lub więcej wcześniejszych schematów anty-her2. Rurociąg z kandydatów na produkty immuno-on-ononologii obejmuje MGC018, koniugat leku przeciwciał (ADC), który jest skierowany do guzów stałych wyrażających B7-H3; Enoblituzumab, przeciwciało monoklonalne, które są ukierunkowane na B7-H3; oraz MGD024, badana bispecyficzna cząsteczka DART CD123 × CD3 w celu zminimalizowania zespołu zwolnienia cytokin u pacjentów z nowotworami hematologicznymi. Opracowuje również Lorigerlimab, przeciwciało monoklonalne, które ukierunkuje się na immunologiczne punkty kontrolne PD-1 i cytotoksyczne białko 4 związane z limfocytem T; Tebotelimab, badana czterowartościowa cząsteczka rzutki dla PD-1 i genu aktywności limfocytów 3; RetifanLimab, badane przeciwciało monoklonalne ukierunkowane na przerzutowe rak płaskonabłonkowy kanału odbytu i przerzutowy niedrobnokomórkowy rak płuc; i IMGC936, ADC, który jest skierowany do ADAM9, białka powierzchniowego komórkowego nadeksprymowanego w różnych typach guzów litych. Ponadto firma opracowuje MGD014 i MGD020, cząsteczkę DART w celu ukierunkowanego na białko otoczki zakażonych komórek zakażonych ludzkiego wirusa niedoboru odporności i CD3 na komórkach T; Teplizumab do leczenia cukrzycy typu 1; i PRV-3279, cząsteczka DART CD32B × CD79B do leczenia wskazań autoimmunologicznych. Współpracuje z Intyte Corporation; Zai Lab Limited; I-MAB Biopharma; oraz Janssen Biotech, Inc. Firma została zarejestrowana w 2000 roku i ma siedzibę w Rockville w stanie Maryland.

Wskaźniki finansowe
Kapitalizacja (USD) 83 594 648
Aktywa: 264 492 000
Cena: 1.32
Wskaźnik Altman Z-Score: -5.1
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -1.5
Ilość akcji w obrocie: 94%
Średni wolumen: 1 178 053
Ilość akcji 63 090 300
Wskaźniki finansowe
Przychody TTM 141 329 000
Zobowiązania: 144 426 000
Przedział 52 tyg.: 0.99 - 5.77
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -0.9
P/E branży: 26.1
Beta: 2.076
Raport okresowy: 2025-08-04
WWW: https://www.macrogenics.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Stephen L. Eck M.D., Ph.D. Senior Vice President of Clinical Development & Chief Medical Officer 766 848 1955
Mr. James Karrels Senior Vice President, Chief Financial Officer & Corporate Secretary 693 306 1967
Mr. Eric Blasius Risser Chief Operating Officer 651 362 1973
Dr. Ezio Bonvini M.D. Senior Vice President of Research & Chief Scientific Officer 612 208 1954
Dr. Thomas M. Spitznagel Ph.D. Senior Vice President of Technical Operations 550 974 1967
Dr. Scott Koenig M.D., Ph.D. President, Chief Executive Officer & Director 1 199 494 1952
Mr. Jeffrey Stuart Peters Senior Vice President, General Counsel & Corporate Compliance Officer 0 1971
Ms. Lynn Cilinski Vice President, Controller & Treasurer 0 1958
Wiadomości dla MacroGenics, Inc.
Tytuł Treść Źródło Aktualizacja Link
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates MacroGenics (MGNX) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.84 per share a year ago. zacks.com 2025-05-13 22:20:38 Czytaj oryginał (ang.)
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2025. globenewswire.com 2025-05-13 20:01:00 Czytaj oryginał (ang.)
MacroGenics Announces Date of First Quarter 2025 Financial Results ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025. globenewswire.com 2025-05-06 20:30:00 Czytaj oryginał (ang.)
MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month: globenewswire.com 2025-05-01 20:30:00 Czytaj oryginał (ang.)
4 Medical Product Stocks to Buy From a Challenging Industry The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors. zacks.com 2025-04-17 13:55:37 Czytaj oryginał (ang.)
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for MacroGenics (MGNX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com 2025-04-03 14:35:48 Czytaj oryginał (ang.)
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for MacroGenics (MGNX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2025-03-20 22:01:03 Czytaj oryginał (ang.)
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates MacroGenics (MGNX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.75 per share a year ago. zacks.com 2025-03-20 21:51:07 Czytaj oryginał (ang.)
MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript MacroGenics, Inc. (NASDAQ:MGNX ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants James Karrels - SVP, CFO and Secretary Scott Koenig - President and CEO Stephen Eck - SVP, Clinical Development & Chief Medical Officer Conference Call Participants Peter Lawson - Barclays Jonathan Chang - Leerink Partners Nicholas Lorusso - TD Cowen Jonathan Miller - Evercore ISI Stephen Willey - Stifel Silvan Tuerkcan - Citizens JMP Securities Mayank Mamtani - B. Riley Securities Operator Good afternoon. seekingalpha.com 2025-03-20 21:09:11 Czytaj oryginał (ang.)
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 20, 2025, at 4:30 pm ET globenewswire.com 2025-03-06 09:30:00 Czytaj oryginał (ang.)
MacroGenics: Stacking Up A Lot Of Headwinds MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate. seekingalpha.com 2025-02-27 16:08:41 Czytaj oryginał (ang.)
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March: globenewswire.com 2025-02-27 09:30:00 Czytaj oryginał (ang.)
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Macrogenics, Inc. (NASDAQ: MGNX) on behalf of long-term stockholders following a class action complaint that was filed against MGNX on July 26, 2024 with a Class Period from March 7, 2024 to May 9, 2024. Our investigation concerns whether the board of directors of MGNX have breached their fiduciary duties to the company. globenewswire.com 2024-12-10 23:00:00 Czytaj oryginał (ang.)
MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month: globenewswire.com 2024-12-02 18:30:00 Czytaj oryginał (ang.)
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: globenewswire.com 2024-11-06 18:30:00 Czytaj oryginał (ang.)
Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2024-11-05 23:00:25 Czytaj oryginał (ang.)
MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates MacroGenics (MGNX) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to loss of $0.52 per share a year ago. zacks.com 2024-11-05 22:31:06 Czytaj oryginał (ang.)
MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants James Karrels - Senior Vice President, Chief Financial Officer and Secretary Scott Koenig - President and Chief Executive Officer Conference Call Participants Nicholas Lorusso - TD Cowen Jonathan Chang - Leerink Partners Reena Patel - Citi Etzer Darout - BMO Capital Markets Jonathan Miller - Evercore ISI Silvan Tuerkcan - Citizens JMP Securities Mayank Mamtani - B. Riley Securities Peter Lawson - Barclays Stephen Willey - Stifel Operator Good afternoon. seekingalpha.com 2024-11-05 21:01:35 Czytaj oryginał (ang.)
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results ROCKVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2024. globenewswire.com 2024-11-05 18:01:00 Czytaj oryginał (ang.)
MacroGenics Announces Leadership Transition ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process. globenewswire.com 2024-10-30 09:30:00 Czytaj oryginał (ang.)
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET. globenewswire.com 2024-10-29 18:30:00 Czytaj oryginał (ang.)
Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders WILMINGTON, DE / ACCESSWIRE / October 25, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ GS:MGNX) on behalf of stockholders. accesswire.com 2024-10-25 21:15:00 Czytaj oryginał (ang.)
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA® ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, announced today that they have entered into an agreement in which TerSera will acquire global rights to MARGENZA® (mar. businesswire.com 2024-10-22 11:30:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). prnewswire.com 2024-09-25 14:00:00 Czytaj oryginał (ang.)
Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MGNX NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104928&wire=1 or contact Joseph E. Levi, Esq. accesswire.com 2024-09-24 23:00:00 Czytaj oryginał (ang.)
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104874&wire=1 or contact Joseph E. Levi, Esq. accesswire.com 2024-09-24 18:15:00 Czytaj oryginał (ang.)
Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). globenewswire.com 2024-09-24 16:57:00 Czytaj oryginał (ang.)
Contact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX) NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104834&wire=1 or contact Joseph E. Levi, Esq. accesswire.com 2024-09-24 15:25:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against MacroGenics, Inc. LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2024. accesswire.com 2024-09-24 15:00:00 Czytaj oryginał (ang.)
MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)--MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm. businesswire.com 2024-09-24 14:30:00 Czytaj oryginał (ang.)
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors - Contact Levi & Korsinsky NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104815&wire=1 or contact Joseph E. Levi, Esq. accesswire.com 2024-09-24 14:15:00 Czytaj oryginał (ang.)
FINAL REMINDER MGNX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts MacroGenics, Inc. Investors to Participate in the Class Action Lawsuit! NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MacroGenics securities between March 7, 2024, and May 9, 2024, inclusive (the "Class Period"). accesswire.com 2024-09-24 14:00:00 Czytaj oryginał (ang.)